Patents Assigned to Lupin Limited
-
Publication number: 20150225380Abstract: The present invention provides a novel method to obtain olmesartan medoxomil (I) with a particle size distribution of less than 30 ?m comprising: dissolving olmesartan medoxomil (I) in a solvent; adding seed crystals of olmesartan medoxomil (I), followed by isolation.Type: ApplicationFiled: July 26, 2013Publication date: August 13, 2015Applicant: LUPIN LIMITEDInventors: Govind Dnyanoba Ausekar, Radhakrishna Bhikaji Shivdavkar, Himanshu Madhav Godbole, Rajendra Vishwanath Firke, Girij Pal Singh
-
Publication number: 20150209432Abstract: The present invention relates to pharmaceutical compositions of Proton Pump Inhibitor and process for preparation of such composition thereof. The invention relates to pharmaceutical compositions comprising Proton Pump Inhibitor, crospovidone, basic inorganic salt and one or more pharmaceutically acceptable excipients. The present invention provides stable pharmaceutical compositions of Dexlansoprazole which are bioequivalent to marketed dual delayed release pharmaceutical compositions of Dexlansoprazole.Type: ApplicationFiled: July 22, 2013Publication date: July 30, 2015Applicant: LUPIN LIMITEDInventors: Kishore Kumar Konda, Pandarinath Jadhav, Satish Kumar Dalal, Shirish Kumar Kulkarni
-
Patent number: 9073942Abstract: Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein A, B, U, R1-R7, m, n, and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.Type: GrantFiled: February 9, 2013Date of Patent: July 7, 2015Assignee: Lupin LimitedInventors: Vidya Ramdas, Advait Arun Joshi, Moloy Manoj Banerjee, Amit Kumar Das, Deepak Sahebrao Walke, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9072731Abstract: Disclosed is a compound of formula (I), wherein Z, m and R1-R6 are as described herein, as a modulator of nicotinic acetylcholine receptors particularly the ?7 subtype, in a subject in need thereof, as well as analogs, prodrugs, isotopically substituted analogs, metabolites, pharmaceutically acceptable salts, polymorphs, solvates, isomers, clathrates, and co-crystal thereof, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds and analogs. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.Type: GrantFiled: February 22, 2012Date of Patent: July 7, 2015Assignee: Lupin LimitedInventors: Neelima Sinha, Gourhari Jana, Sachchidanand Sachchidanand, Sanjay Pralhad Kurhade, Navnath Popat Karche, Anil Kashiram Hajare, Ajay Ramchandra Tilekar, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9073943Abstract: Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein R-R 6 and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds. (I).Type: GrantFiled: February 8, 2013Date of Patent: July 7, 2015Assignee: Lupin LimitedInventors: Vidya Ramdas, Advait Arun Joshi, Moloy Manoj Banerjee, Amit Kumar Das, Deepak Sahebrao Walke, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9062065Abstract: The present invention provides a novel process for preparation of darunavir that involves reduction of [(1S,2R)-3-[[(4-nitrophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamic acid (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, of formula (5). The present invention also provides darunavir ethanolate of particle size wherein d0.9 is less than 130 ?m, d0.5 is less than 30 ?m, d0.1 is less than 10 ?m and process for its preparation.Type: GrantFiled: November 1, 2010Date of Patent: June 23, 2015Assignee: LUPIN LIMITEDInventors: Vijay Ahire, Sachin Sasane, Amol Deshmukh, Krishnat Kumbhar, Akshat Bhatnagar, Devendra Verma, Rajesh Vyas, Girij Pal Singh, Nandu Bhise
-
Patent number: 9062067Abstract: The present invention provides a novel process for preparation of darunavir that involves reduction of [(1S,2R)-3-[[(4-nitrophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamic acid (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, of formula (5). The present invention also provides darunavir ethanolate of particle size wherein d0.9 is less than 130 ?m, d0.5 is less than 30 ?m, d0.1 is less than 10 ?m and process for its preparation.Type: GrantFiled: November 8, 2013Date of Patent: June 23, 2015Assignee: LUPIN LIMITEDInventors: Vijay Ahire, Sachin Sasane, Amol Deshmukh, Krishnat Kumbhar, Akshat Bhatnagar, Devendra Verma, Rajesh Vyas, Girij Pal Singh, Nandu Bhise
-
Publication number: 20150152118Abstract: Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, R7a-d, R8a-d, A, M, n, and p are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.Type: ApplicationFiled: July 9, 2013Publication date: June 4, 2015Applicant: LUPIN LIMITEDInventors: Gourhari Jana, Sanjay Pralhad Kurhade, Arun Rangnath Jagdale, Gagan Kukreja, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9040089Abstract: A taste masked pharmaceutical composition of clindamycin, or a pharmaceutically acceptable salt(s), hydrate(s), solvate(s) and physiologically functional derivative(s) and precursors thereof, which includes all polymorphic forms, whether crystalline or amorphous comprising polyhydric alcohol(s); and one or more other pharmaceutically acceptable excipient(s). A process for preparation of a taste masked pharmaceutical composition of clindamycin or a pharmaceutically acceptable salt(s) thereof the said process comprising the steps of a) dry mixing clindamycin, polyhydric alcohol and other pharmaceutically acceptable excipient(s) to get a dry mixture; b) granulating the dry mixture above with a granulating liquid prepared by mixing the suitable pharmaceutically acceptable excipient(s) with aqueous/non-aqueous fluid to obtain a wet mass; c) drying the wet mass to obtain the discrete particles; d) lubricating the discrete particles obtained with a suitable lubricating agent and/or flavor(s).Type: GrantFiled: September 10, 2008Date of Patent: May 26, 2015Assignee: LUPIN LIMITEDInventors: Kalpana Walzade, Rajesh Kulkarni, Shirishkumar Kulkarni
-
Patent number: 9040688Abstract: The process of the present invention relates to a method for the synthesis of a 1,4-diphenylazetidinone of formula (VIII) by using novel oxime intermediates.Type: GrantFiled: March 31, 2010Date of Patent: May 26, 2015Assignee: LUPIN LIMITEDInventors: Dhananjai Srivastava, Rajiv Kumar Shakya, Namrata Anil Chaudhari, Inamus Saqlain Ansari, Girij Pal Singh
-
Patent number: 9028865Abstract: A controlled release pharmaceutical composition which comprises therapeutically effective amount of pregabalin or salts thereof as active ingredient, a hydrophobic release controlling agent(s) and optionally other pharmaceutically acceptable excipients thereof.Type: GrantFiled: May 31, 2013Date of Patent: May 12, 2015Assignee: Lupin LimitedInventors: Rahul Manorajan Sammohi, Nikhil Prabhakar Malewar, Makarand Krishnakumar Avachat
-
Patent number: 9006442Abstract: Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors of Formula (I).Type: GrantFiled: July 5, 2012Date of Patent: April 14, 2015Assignee: Lupin LimitedInventors: Sanjeev Anant Kulkarni, Sachin Madan, Nirmal Kumar Jana, Prashant Vitthalrao Tale, Narasimha Murthy Cheemala, Sachin Jaysing Mahangare, Prashant Popatrao Vidhate, Chaitanya Prabhakar Kulkarni, Sapana Suresh Patel, Amolsing Dattu Patil, Seema Prabhakar Zade, Rohan Mahadev Shinde, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9000175Abstract: The present invention relates to compounds of Formula (I) that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of GPR119 receptor activity. The invention also relates to the process for preparation of the compounds, pharmaceutical compositions thereof. The invention further relates to methods of treating, preventing and/or managing diseases, disorders syndromes or conditions associated with the modulation of GPR119 receptor by using either alone or in combinations of Formula (I).Type: GrantFiled: November 24, 2011Date of Patent: April 7, 2015Assignee: Lupin LimitedInventors: Rajesh Thotapally, Onkar Gangaram Kachi, Atish Harishchandra Rodge, Ashok Bhau Pathak, Bhavana Shrirang Kardile, Milind Dattatraya Sindkhedkar, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 8981110Abstract: The present invention provides novel process for preparation of olmesartan medoxomil (I) substantially free of olmesartan acid impurity (II) comprising, reacting trityl olmesartan medoxomil (III) with acid, filtering the precipitate of trityl alcohol, subjecting the filtrate to agitated thin film drying and recovering olmesartan medoxomil (I).Type: GrantFiled: July 31, 2012Date of Patent: March 17, 2015Assignee: Lupin LimitedInventors: Rajendra Vishwanath Firke, Ujjwal Komalsing Sisodiya, Chandrakant Shriram Bhangale, Radhakrishna Bhikaji Shivdavkar, Himanshu Madhav Godbole, Girij Pal Singh
-
Patent number: 8974825Abstract: A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract.Type: GrantFiled: June 24, 2008Date of Patent: March 10, 2015Assignee: Lupin LimitedInventors: Harshal Anil Jahagirdar, Rajesh Kulkarni, Shirishkumar Kulkarni
-
Patent number: 8946432Abstract: Disclosed is a compound of formula (I): wherein ‘D’, ‘E’, ‘m’, ‘n’ and R1-R4 are as described herein, as a modulator of nicotinic acetylcholine receptors particularly the ?7 subtype, in a subject in need thereof, as well as analogues, prodrugs, isotopically substituted analogs, metabolites, pharmaceutically acceptable salts, polymorphs, solvates, isomers, clathrates, and co-crystal thereof, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds and analogues. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.Type: GrantFiled: July 2, 2012Date of Patent: February 3, 2015Assignee: Lupin LimitedInventors: Neelima Sinha, Navnath Popat Karche, Girish Dhanraj Hatnapure, Anil Kashiram Hajare, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20150010504Abstract: Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein A, B, U, R1-R7, m, n, and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.Type: ApplicationFiled: February 9, 2013Publication date: January 8, 2015Applicant: Lupin LimitedInventors: Vidya Ramdas, Advait Arun Joshi, Moloy Manoj Banerjee, Amit Kumar Das, Deepak Sahebrao Walke, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20150010505Abstract: Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein R-R 6 and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds. (I).Type: ApplicationFiled: February 8, 2013Publication date: January 8, 2015Applicant: LUPIN LIMITEDInventors: Vidya Ramdas, Advait Arun Joshi, Moloy Manoj Banerjee, Amit Kumar Das, Deepak Sahebrao Walke, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 8916194Abstract: A controlled release pharmaceutical compositions comprising Milnacipran or pharmaceutically acceptable salts thereof is provided. The pharmaceutical composition comprises an immediate release core comprising Milnacipran or pharmaceutically acceptable salts thereof, pharmaceutically acceptable excipients and a coating on the immediate release core comprising rate controlling agents.Type: GrantFiled: August 26, 2011Date of Patent: December 23, 2014Assignee: Lupin LimitedInventors: Shirishkumar Kulkarni, Rajesh Kulkarni, Pandharinath Jadhav, Ashish Tiwari
-
Publication number: 20140357871Abstract: The present invention relates to a novel process for preparation of rufinamide (I) comprising: reacting 2,6-difluorobenzyl azide (II) and propiolic acid (III) in a mixture of alcohol and water to produce 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxylic acid (IV), esterifying the acid (IV) to ester (V) and treating ester (V) with ammonia. The invention further relates to process for purification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxylic acid (IV), by crystallization from a mixture of alcohol and water. The present invention also provides process for purification of rufinamide (I) by crystallization from mixture of polar aprotic solvent with water or alcohol.Type: ApplicationFiled: January 9, 2013Publication date: December 4, 2014Applicant: LUPIN LIMITEDInventors: Rajinder Singh Siyan, Yogesh Subhas Aher, Nandu Baban Bhise, Girij Pal Singh, Sunilkumar Vinubhai Gohel